Citrobacter freundii complex, Staphylococcus saprophyticus and Enterococcus faecalis. Blujepa is the first in a new class of oral antibiotics for uncomplicated urinary tract infections approved in ...
FDA Approves GSK' Blujepa For Treating Uncomplicated Urinary Tract Infections In Women & Adolescents
Citrobacter freundii complex, Staphylococcus saprophyticus and Enterococcus faecalis. US commercial launch is planned in the second-half of 2025. Uncomplicated urinary tract infections are the ...
Blujepa, a first-in-class oral antibiotic, is approved for treatment of uUTIs caused by Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii complex, Staphylococcus saprophyticus ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback